Skip to main content
OpenTrials
Completed

NCT Number: NCT05295875

Efficacy and Safety of ALT-801 in the Treatment of Obesity

This study will evaluate the efficacy and safety of ALT-801 once-weekly versus placebo as an adjunct to a reduced-calorie diet and increased physical activity in patients with obesity/overweight.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Altimmune CTM, Birmingham, Alabama, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Written informed consent signed prior to entry into the study
  • Male or female age 18 to 75 years, inclusive
  • Body mass index (BMI) ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 combined with at least one obesity-related comorbidity
  • At least one unsuccessful weight loss attempt per investigator judgement
  • Agreement to comply with the study-required life-style intervention and treatment during the full duration of the study
  • Female subjects of childbearing potential who are not pregnant or breastfeeding, do not plan to become pregnant during the study, and agree to use effective birth control

Exclusion criteria

  • Weight gain or loss > 5% in the 3 months prior to randomization or >10% in the 6 months prior to screening
  • Diabetes and related conditions:
  • History or clinical evidence of diabetes mellitus of any type, including Type 1, Type 2, or mature onset diabetes of the young (MODY)
  • HbA1c > 6.5%, fasting glucose ≥ 126 mg/dL (6.9 mmol/L), and/or random glucose of ≥ 200 mg/dL (11.0mmol/L) at screening
  • Obesity and related conditions:
  • Obesity induced by known genetic causes or endocrine disorders (eg, Cushing Syndrome, inadequately treated hypothyroidism, defined as thyroid-stimulating hormone [TSH] > 6 mIU/L)
  • History of bariatric surgery or other surgical treatment for obesity (eg, gastric banding, gastric bypass), or planned surgery or surgical treatment during the study. Liposuction and/or abdominoplasty performed >1 year before screening is allowed. Endoscopically placed intragastric balloons will be allowed if removed > 1 year before screening.
  • Gastrointestinal conditions:
  • History of acute or chronic pancreatitis within 1 year (365 days) before screening
  • History of or acute significant gastrointestinal (GI) disorder (eg, peptic ulcers, severe gastroesophageal reflux disease [GERD],
  • History of GI surgery, including cholecystectomy and antrectomy. Surgery for appendicitis and small bowel resection >20cm is acceptable.
  • History of inflammatory bowel disease, celiac disease or any medical condition or surgery that could affect gastric emptying, stool frequency or stool consistency. (Irritable bowel syndrome is permitted provided that bowel frequency and consistency are normal off treatment.)
  • Mental health conditions:
  • Untreated depressive disorder, defined as a Patient Health Questionaire-9 (PHQ-9) score of ≥ 15 at screening
  • Suicide ideation, defined as type 4 or 5 on the Columbia-Suicide Severity Rating Scale(C-SSRS) at screening, lifelong history of a suicide attempt, or suicidal behavior within 30 days before screening
  • Other severe psychiatric disorder (eg, schizophrenia, bipolar disorder)

Treatment and study plan

ALT-801

Drug

Injected subcutaneously (SC)

Placebo

Other

Injected subcutaneously (SC)

Primary outcomes

  1. Relative change from baseline in body weight percentage

    Time frame: Baseline to Week 48

Secondary outcomes

  1. Percent proportion of subjects with weight loss of greater than or equal to 5%, 10%, and 15%

    Time frame: Baseline to Week 48

  2. Change from baseline in lipids

    Time frame: Baseline to Week 48

  3. The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Baseline to Week 48

  4. Changes from baseline in Fasting Glucose

    Time frame: Baseline to Week 48

  5. Changes from baseline in Hemoglobin A1c

    Time frame: Baseline to Week 48

  6. Changes from baseline in Homeostatic Marker Assessment for Insulin Resistance (HOMA-IR)

    Time frame: Baseline to Week 48

  7. Changes from baseline in: a) Systolic blood pressure, b) Diastolic blood pressure

    Time frame: Baseline to Week 48

  8. Change from baseline in proportion of patients using antihypertensive medications

    Time frame: Baseline to Week 48

Sponsors and collaborators

Lead sponsor

Altimmune, Inc.

Industry

Registry information

Official study title

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled and Parallel Group 48-Week Study to Evaluate the Efficacy and Safety of ALT-801 in the Treatment of Obesity (MOMENTUM Trial)

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Mar 25, 2022
Registry last updated
Nov 29, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.